Upadacitinib treatment in patients with moderate to severe atopic dermatitis: A retrospective single-centre Australian review of 14 patients post phase 3 clinical trial

被引：2
|
作者：
Bennett, Michaela [1 ,3 ]
Sinclair, Rodney D. [1 ,2 ]
Eisman, Samantha [1 ]
机构：
[1] Sinclair Dermatol, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Level 3,2 Wellington Parade, East Melbourne 3002, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷 / 01期
关键词：
atopic dermatitis; JAK; 1; inhibitors; JAK inhibitor treatment; Upadacitinib;
D O I：
10.1111/ajd.13969
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Recent phase 2b and phase 3 clinical trials support the safety and efficacy of the selective Janus kinase (JAK)-1 inhibitor upadacitinib (UPA) in the treatment of moderate to severe atopic dermatitis (AD). However, to date, there is little experience with UPA therapy for AD in Australia. We report findings from a retrospective study to better understand the therapeutic response and side effects noted in a single-centre Australian cohort.
引用
收藏
页码：146 / 150
页数：5
相关论文
共 50 条
  • [31] Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB72 - AB72
  • [32] Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    Bangert, Christine
    Irvine, Alan D.
    Weidinger, Stephan
    Johnson, Susan
    Lazariciu, Irina
    Koppensteiner, Herwig
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 77
  • [33] Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study
    Hosseini-Ashrafi, Mozhgan
    Clayton, Tim H.
    Herring, Michelle
    Herety, Nichola
    Arkwright, Peter D.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (06) : 578 - 583
  • [34] Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials
    Mendes-Bastos, Pedro
    Ladizinski, Barry
    Guttman-Yassky, Emma
    Jiang, Ping
    Liu, John
    Prajapati, Vimal H.
    Simpson, Eric L.
    Vigna, Namita
    Teixeira, Henrique D.
    Barbarot, Sebastien
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 784 - 791
  • [35] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial
    Li, Hang
    Cheng, Hao
    Lu, Qianjin
    Lai, Wei
    Tao, Xiaohua
    Encinas, Gerardo A.
    Vyas, Shefali
    Wang, Bo
    Luo, Xin
    Li, Shiqi
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [36] Achieving a deep response on patient-reported outcomes with upadacitinib in patients with moderate to severe atopic dermatitis: Results from three phase 3 trials
    Chovatiya, Raj
    Schuttelaar, Marie-Louise
    Calimlim, Brian
    Liu, Yingyi
    Takemoto, Shunya
    Staender, Sonja
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1017 - 1018
  • [37] Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial
    Simpson, Eric L.
    Paller, Amy S.
    Siegfried, Elaine C.
    Boguniewicz, Mark
    Sher, Lawrence
    Gooderham, Melinda J.
    Beck, Lisa A.
    Guttman-Yassky, Emma
    Pariser, David
    Blauvelt, Andrew
    Weisman, Jamie
    Lockshin, Benjamin
    Hultsch, Thomas
    Zhang, Qin
    Kamal, Mohamed A.
    Davis, John D.
    Akinlade, Bolanle
    Staudinger, Heribert
    Hamilton, Jennifer D.
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Gadkari, Abhijit
    Eckert, Laurent
    Stahl, Neil
    Yancopoulos, George D.
    Ruddy, Marcella
    Bansal, Ashish
    JAMA DERMATOLOGY, 2020, 156 (01) : 44 - 56
  • [38] Peak Pruritus Numeric Rating Scale response with abrocitinib in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial
    Simpson, Eric L.
    Staender, Sonja
    Yosipovitch, Gil
    Cameron, Michael C.
    DiBonaventura, Marco
    Williams, David
    Tatulych, Svitlana
    Nduaka, Chudy
    Valdez, Hernan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB61 - AB61
  • [39] Dupilumab treatment induces rapid clinical improvement of itch in patients with moderate-to-severe atopic dermatitis
    Silverberg, Jonathan I.
    Eckert, Laurent
    Ardeleanu, Marius
    Chen, Zhen
    Akinlade, Bolanle
    Plaum, Stefan
    Graham, Neil M. H.
    Pirozi, Gianluca
    Gadkari, Abhijit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB113 - AB113
  • [40] Tralokinumab prevents flares in moderate-to-severe atopic dermatitis: post hoc analyses of a randomized phase III clinical trial (ECZTRA 3)
    Silverberg, J. I.
    Barbarot, S.
    Welzel, J.
    Ameen, M.
    Thyssen, J. P.
    Lomaga, M.
    Olsen, C. Kurre
    Mark, T.
    Corriveau, J.
    Merola, J. F.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E79 - E79
12345